weight loss
[대역어] None
[용어속성] Symptom
[용어속성] Symptom
Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant
Article
[키워드] Activation
acute respiratory syndrome
analysis
Beta
Beta variant
blockade
cascade
cause
CCL2
Characteristics
Comparative analysis
coronavirus
coronavirus 2
COVID-19
COVID-19 pandemic
CXCR2
cytokine
cytokine release
death
Disease progression
early stage
evidenced
IL-1β
immunological
induce
Infection
Inflammatory cytokine
investigated
K18-hACE2
late stage
Lung pathology
mice
molecular mechanism
Mortality
neutrophil recruitment
outbreak
pathological
pathological condition
pathology
phenotype
presymptomatic
provide
reduced
respiratory
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 pathogenesis
SARS-CoV-2 variant
secreted cytokine
Strains
the SARS-CoV-2
Transcriptome
transcriptomes
Transmissibility
Treatment
variant
Variant.
viral infection
weight loss
[DOI] 10.1128/spectrum.02371-22 PMC 바로가기
[DOI] 10.1128/spectrum.02371-22 PMC 바로가기
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
Article
[키워드] ACM
acute respiratory syndrome
adverse effect
airway
antibodies
antibody
antigen presenting cells
artificial
Beta
Beta spike
C57BL/6
cell membrane
clinical symptom
clinical trial
component
conditions
coronavirus
coronavirus disease
COVID-19
CpG
cross-neutralizing
current
delivery of cargo
dendritic cells
dose
doses
evaluate
evaluated
Formulation
generate
Generation
Good
hamster
hamsters
immune responses
immunization
immunogenic
induce
Infection
initiated
interval
intranasal
mice
neutralize
neutralizing antibody
neutralizing responses
New
omicron
Phase 1
polymersome
Practice
PROTECT
reduction
repeated
Safety
SARS-CoV-2
second
serum IgG
spike
Spike protein
Spike-based vaccine
Support
Toxicity
upper respiratory tract
Vaccine
vaccine.
variants
viral clearance
Viral load
virus
weight loss
wild type
[DOI] 10.1021/acsnano.2c06350 PMC 바로가기
[DOI] 10.1021/acsnano.2c06350 PMC 바로가기
Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor
시험관 내 및 생체 내에서 SARS-CoV-2 감염에 대한 선택적 에스트로겐 수용체 조절제의 항바이러스 효능은 진입 억제제로서 바제독시펜 아세테이트를 나타냅니다
Article
[키워드] Acetate
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
anti-SARS-CoV-2
antiviral efficacy
Bazedoxifene
bazedoxifene acetate
candidate
cholesterol
cholesterol distribution
citrate
clinical
Clomifene
Clomifene citrate
contagious
coronavirus
Coronaviruses
Critical
delta variant
distribution
drugs
Effect
Efficacy
endosome acidification
Estrogen
estrogen receptor
evaluated
exhibited
expression
hamster
hamsters
human cell lines
humans
identify
in vitro
in vivo
infect
Infection
information
inhibited
inhibitor
interleukin-6
offer
omicron
Omicron variant
pathogenic variant
penetration
Postinfection
pseudovirus
pseudoviruses
pulmonary viral
reduced
reveal
SARS-CoV
SARS-CoV-2
SARS-COV-2 infection
selective
selective estrogen receptor modulator
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome coronavirus 2.
Tamoxifen
toremifene
toremifene citrate
variant
Vero E6
Vero E6 cell
VERO E6 cells
weight loss
[DOI] 10.1002/jmv.27951 PMC 바로가기 [Article Type] Article
[DOI] 10.1002/jmv.27951 PMC 바로가기 [Article Type] Article
Obesity is associated with a higher Torque Teno viral load compared to leanness
Article
[키워드] 95% CI
acute respiratory syndrome
Affect
age
Analysis
association
Bariatric surgery
BMI
confounder
coronavirus
coronavirus disease
disease
disease-associated
Diseases
fasting insulin
Follow-up
Host
immune function
immunocompetence
in viral
independent
individual
Infectious disease
interleukin 6
IQR
linear modeling
marker
median
obese
obesity
outcome
outcomes
participant
PCR
positively correlated
proportion
quantified
reflect
rising
risk
risk factor
risk stratification
subjects
torque
torque teno virus
viral immune response
Viral load
virus
vitamin D levels
weight loss
Weight loss.
[DOI] 10.3389/fendo.2022.962090 PMC 바로가기
[DOI] 10.3389/fendo.2022.962090 PMC 바로가기
Aseptic Abscess Syndrome in Rheumatoid Arthritis Patient
Article
[키워드] abdominal pain
abscess
accompanied
adalimumab
Antibiotics
Aseptic
aseptic abscess syndrome
Autoimmune diseases
Bacteria
characterized
Clinical improvement
Complete
corticosteroid therapy
COVID-19 infection
disorder
extension
feature
Fever
IBD
include
Inflammatory
Inflammatory bowel disease
Inflammatory marker
internal organ
joints
lack
lesion
lesions
Leukocytosis
liver
Lungs
microbe
neutrophilic
parasites
Patient
potentially life-threatening
Practitioner
Prednisone
recognize
reduction
Remdesivir
Rheumatoid
rheumatoid arthritis
rheumatoid arthritis.
sensitivity
spleen
Symptom
syndrome
systemic symptom
tissue
treated
Treatment
viruses
weight loss
[DOI] 10.3390/medicina58101354 PMC 바로가기
[DOI] 10.3390/medicina58101354 PMC 바로가기
Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma
Article
[키워드] abdominal pain
absence
advanced age
Anemia
anorexia
Antibiotics
B cell
Blood
bone
Bone marrow
Cell
Chemotherapy
Clinical deterioration
Combination
COVID-19
Culture
Cyclophosphamide
Diagnosis
diarrhea
died
diffuse
DLBCL
Doxorubicin
elevated
fatigue
Fever
G-CSF
granulocyte
IMPROVE
Infection
inflammation markers
initiated
lymphoma
malignancy
management
Marrow
NHL
Non-Hodgkin Lymphoma
Pancytopenia
Patient
patient with COVID-19
PCR
Platelet
positive
Prednisone
Prognosis
rituximab
Thoracic
tomography
Treatment
vincristine
watery
weight loss
while
White blood cell
worsening
[DOI] 10.12659/AJCR.937500 PMC 바로가기
[DOI] 10.12659/AJCR.937500 PMC 바로가기
Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters
Article
[키워드] angiotensin-converting enzyme 2
Blood
controls
coronavirus disease
Coronavirus disease 2019
COVID-19
days post-infection
disease
early stage
Efficacy
exhibited
favor
fibrosis
form
hamster
hamsters
hepatocyte ballooning
impair
induce
infected with SARS-CoV-2
Infection
Inflammation
Inflammatory cytokines
less
liver
Liver fibrosis
liver steatosis
long-lasting
Lung inflammation
lung viral load
mechanism
NASH
non-alcoholic steatohepatitis
obese
obese patient
obesity
obesity.
pathophysiologic
Patient
pulmonary fibrosis
relative
replicate
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-infected hamsters
Serum level
severity of COVID-19
steatohepatitis
sustained
systemic inflammation
the SARS-CoV-2
Treatment
weight loss
[DOI] 10.3390/v14092067 PMC 바로가기
[DOI] 10.3390/v14092067 PMC 바로가기
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
Article
[키워드] Affect
antibody production
B.1.1.529
B.1.1.7 lineage
B.1.351
B.1.427
B.1.429
B.1.617.2
Beta
coronavirus
COVID-19
COVID-19 vaccine
Delta
delta variant
demonstrated
develop
disease severity
domain
effective
effective vaccine
Effectiveness
Efficacy
elicited
enhanced
enhanced protection
epitope
Epsilon
Gamma
global public health
highlight
human ACE2
immunized
immunized mice
immunodominant
IMPROVE
Improved
improved neutralizing activity
induce
Lineage
mice
mutant
mutated
Mutation
Neutralizing
Neutralizing activity
neutralizing antibody
Neutralizing antibody titer
Numerous
omicron
Omicron and other variants
Other
P.1
pandemic
Prevent
probe
protection
Protective
Protein
pseudotyped
pseudovirus
RBD
RBD protein
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 spike protein
SARS-CoV-2 strain
SARS-CoV-2 variant
SARS-CoV-2 variants
shown
significantly
Strains
subunit
Subunit vaccine.
the receptor-binding domain
threat
Transmissibility
Vaccine
variant
variants
weight loss
[DOI] 10.1128/jvi.00118-22 PMC 바로가기
[DOI] 10.1128/jvi.00118-22 PMC 바로가기
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Article
[키워드] acute respiratory syndrome
amino acid substitution
amubarvimab (BRII-196)
antibody
antibody cocktail
Clinical efficacy
Combination
controls
coronavirus
coronavirus disease
COVID-19
demonstrated
Emergency use authorization
epitope
EUA
Evolution
half-maximal inhibitory concentration
half-maximal inhibitory concentration (IC50)
in vitro
introduced
less
Lung pathology
Lungs
M252Y/S254T/T256E (YTE)
mAb
mAbs
Modification
monoclonal antibody
monoclonal antibody (mAb)
Mutation
neutralize
neutralized
Neutralizing
Post-infection
Preclinical
RBD
receiving
Receptor binding domain
receptor binding domain (RBD)
reduce
reduced
regions
regulatory authority
resulting
retained
romlusevimab (BRII-198)
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variants
serum
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
significantly
Spike protein
Support
susceptibility
therapeutic option
variant
Variant of concern (VOC).
variants
variants of concern
Viral load
virus
virus
VoC
weight loss
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기